Adalimumab for nail psoriasis: Efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
Journal of the European Academy of Dermatology and Venereology | Jul 19, 2019
A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
Journal of the American Academy of Dermatology | Jul 18, 2019